CervoMed公司宣布,其研发的候选药物Neflamapimod已被遴选加入英国Experts-ALS平台。该平台的核心目标在于识别并优先推进针对肌萎缩侧索硬化症(ALS)最具前景的治疗方案。
CervoMed公司宣布,其研发的候选药物Neflamapimod已被遴选加入英国Experts-ALS平台。该平台的核心目标在于识别并优先推进针对肌萎缩侧索硬化症(ALS)最具前景的治疗方案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.